CorMedix Inc. (AMEX:CRMD) headquartered in Berkeley Heights, will host a conference call for the investment community to discuss the 3Q20 earnings result on 5th November 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.cormedix.com
Earnings Expectation
CorMedix Inc. is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CRMD to report 3Q20 loss of $ 0.25 per share. For the full year, analysts anticipate top line of $ 0.17 million, while looking forward to loss of $ 0.93 per share bottom line.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc.
